 Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| GnRH-leukotoxin chimeras |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| GNRH-leukotoxin chimeras |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| Polynucleotides encoding LKT 111 |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| Methods and compositions for the treatment of defects in lipoprotein metabolism |
| In one aspect, the invention provides a recombinant viral vector comprising the DNA of, or ... |
|
| Antisera against a PEB1 antigen from Campylobacter jejuni |
| It is an object of the present invention to provide highly specific and highly sensitive diagnostic ... |
|
| Gene encoding invasion protein of campylobacter species |
| OF PREFERRED EMBODIMENTS The following standard abbreviations for the amino acid residues are used ... |
|
| Preservatives for vaccines |
| New combinations of preservatives that pass antimicrobial testing requirements for United States P... |
|
| Methods and reagents for HLA class I A locus DNA typing |
| OF THE INVENTION To aid in understanding the invention, several terms are defined below. The terms ... |
|
| Immunomodulating compounds comprising d-isomers of amino acids |
| What is claimed is: 1. A peptide compound having immunomodulating activity comprising the sequence: ... |
|
|
Recombinant vector containing a sequence of a lipoprotein gene for the expression of nucleotide sequences
| Details |
Inventors: Hamers, Raymond; Cornelis, Pierre;
Assignee:
Primary Examiner: Hutzell; Paula K.
Assistant Examiner: Lazar-Wesley; Eliane
Attorney, Agent or Firm: Birch, Stewart, Kolasch & Birch, LLP
A recombinant vector for cloning a heterologous nucleotide sequence and/or expressing it and/or transferring it to a cell host. The vector includes, at a site which is not essential for replication, the gene coding for a lipoprotein other than E. coli lipoproteins, or a part of said gene which contains the elements required for controlling the expression of said lipoprotein and exposing it on the surface of the outer host cell membrane, so that the heterologous nucleotide sequence can be inserted into the gene or said part thereof under conditions suitable for expressing said heterologous sequence and exposing it on the surface of the cell host. |
|
DETAILED DESCRIPTION We claim: 1.
A recombinant vector for the cloning, expression, and exposure at the surface of the external membrane of Gram-negative bacteria of a heterologous polypeptide, said vector comprising a nucleotide sequence encoding a fusion protein consisting of the major lipoprotein of the external membrane of the P.
aeruginosa, OprI, and the heteologous polypeptide.
2.
The recombinant vector according to claim 1, wherein said vector is a plasmid.
3.
The recombinant vector according to claim 1 or 2, wherein the lipoprotein OprI is heterologous in relation to the cell host containing the vector.
4.
The recombinant vector according to claim 1 or 2, wherein the nucleotide sequence encoding said major lipoprotein is modified with one or more restriction sites.
5.
The recombinant vector according to claim 1, wherein the expression of the nucleotide sequence encoding the heterologous polypeptide is constitutive.
6.
The recombinant vector according to claim 1, which is plasmid pLPI34 deposited at BCCM (LMBP) under the No.
LMBP2916.
7.
The recombinant vector according to claim 1, which is plasmid pLPI35 or plasmid pLPI36.
8.
The recombinant vector according to claim 1, which is vector pVUB1 or vector pVUB2.
9.
The recombinant vector according to claim 1, wherein the nucleotide sequence encoding the heterologous polypeptide encodes an amino acid sequence containing one or more antigenic determinants or one or more haptens.
10.
The recombinant vector according to claim 9, wherein the nucleotide sequence encoding the heterologous polypeptide encodes a type B epitope, a type T epitope or both, of determined antigens of pathogenic agents.
11.
The recombinant vector according to claim 1, wherein the nucleotide sequence encoding the heterologous polypeptide encodes an amino acid sequence of a heavy chain of an antibody or of a light chain of an antibody.
12.
The recombinant vector according to claim 1, wherein the nucleotide sequence encoding the heterologous polypeptide encodes an antibody consisting exclusively of heavy chains
|
| Related patents |
|
|
Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
Surprisingly, it was found by the inventors that a hybrid protein, wherein OprI is linked with its N-terminal end to a C-terminal portion of OprF is significantly more ...
|
|
|
LktA deletion mutant of P. haemolytica
It is an object of the present invention to provide a P. haemolytica bacterium useful as a vaccine strain. It is another object of the present invention to provide a ...
|
|
|
Malaria vaccine
OF THE INVENTION It has been established that a mixture of the following novel peptide compounds represents a preferred embodiment of the present invention, namely, Tyr-...
|
|
|
Protein copolymer malaria vaccine
OF THE INVENTION It has been established that a mixture of the following novel peptide compounds represents a preferred embodiment of the present invention, namely, F...
|
|
|
Vaccine against the sporozoite stage of malaria
OF THE INVENTION The P.vivax CS gene is set forth below (together with the amino acid sequence for which its codes) ##STR1## The DNA fragment chosen for insertion in ...
|
|
|
Malaria antigen
We claim: 1. A substantially pure polypeptide comprising the amino acid sequence of a glutamate-rich polypeptide (GLURP) derived from a Plasmodium falciparum antigen ("...
|
|
|
Oligopeptide lyophilisate, their preparation and use
OF PREFERRED EMBODIMENTS The following Examples illustrate the invention. EXAMPLE 1 Approx. 1.5 liters of water for injection purposes are prepared in a suitable glass ...
|
|
|
Antithrombin nucleotides and proteins from horn fly
Isolated proteins with antithrombin activity and nucleotide sequences encoding the proteins are provided. The protein named thrombostasin is isolated from the salivary ...
|
|
|
Immunogenic conjugates comprising leukotoxin peptide fragments
OF THE INVENTION Substances having molecular weights less than 1000 daltons are not ordinarily antigenic. However, antibodies can be raised to small molecules by ...
|
|
|
Interleukin-2-leukotoxin gene fusions and uses thereof
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA ...
|
|
|
Drugs 
